

1645/DPW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT				Docket No. 18611	
Under 37 CFR 1.97(b) or 1.97(c)					
In Re Application Of: Louis Schofield AUG 06 2007					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,494	September 9, 2005	Rodney P. Swartz	23389	1645	4482
Title: IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENTDocket No.
18611

(Under 37 CFR 1.97(b) or 1.97(c))

In Re Application of: Louis Schofield

AUG 06 2007

Application No. Filing Date

10/522,494

September 9, 2005

Examiner

Rodney P. Swartz

Customer No.

23389

Group Art Unit

1645

Confirmation No.

4482

Title:

IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

August 2, 2007
(Date)

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Mark J. Cohen
Registration No. 32,211
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

Dated: August 2, 2007

cc:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Louis Schofield

Examiner: Rodney P. Swartz

Serial No: 10/522,494

Art Unit: 1645

Filed: September 9, 2005

Docket: 18611

For: IMMUNOGENIC COMPOSITIONS AND
DIAGNOSTIC AND THERAPEUTIC USES
THEREOF

Dated: August 2, 2007

Confirmation No.: 4482

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. German Publication No. 43 11 580 C1, published August 18, 1994, together with an English-language abstract;
2. Naik R.S. et al., "Glycosylphosphatidylinositol Anchors of *Plasmodium falciparum*: Molecular Characterization and Naturally Elicited Antibody Response that May Provide Immunity to Malaria Pathogenesis", *The Journal of Experimental Medicine* 192(11):1563-1575 (2000);
3. Vafai A., "Boosting Immune Response with a Candidate Varicella-Zoster Virus Glycoprotein Subunit Vaccine", *Vaccine* 13(14):1336-1338 (1995);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner of Patents, Alexandria, VA 22313-1450.


Dated: August 2, 2007


Mark J. Cohen

4. PCT International Publication No. WO 00/24406, published May 4, 2000;
5. PCT International Publication No. WO 00/15254, published March 23, 2000;
6. Romero G. et al., "Anti-Inositolglycan Antibodies Selectively Block Some of the Actions of Insulin in Intact BC₃H1 Cells", *Proc. Natl. Acad. Sci. USA* 87:1476-1480 (1990); and
7. Schofield L. et al., "Synthetic GPI as a Candidate Anti-toxic Vaccine in a Model of Malaria", *Nature* 418:785-789 (2002).

References 1-4 were cited in a Supplementary Partial Search Report dated February 9, 2006 received from the European Patent Office. References 1-6 were cited in a First Examination Report issued May 13, 2005 with respect to the corresponding Indian Patent Application No. 671/DELNP/2005. Applicants are submitting copies of the above-cited references as well as copies of the Supplementary Partial European Search Report and the First Examination Report. References 2, 5, 6 and 7 were cited in an International Search Report dated September 13, 2003 and the International Preliminary Examination Report dated November 1, 2004, both received from the Australian Patent Office. Applicants previously submitted a copy of the International Preliminary Examination Report and the International Search Report on January 26, 2005.


Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,

Mark J. Cohen
Registration No.: 32,211

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
PIB:dg

PTO-1449
(7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)

**Atty. Docket No.**

18611

Serial No.

10/522,494

Applicants

Louis Schofield

Filing Date

September 9, 2005

Group Art Unit

1645

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		43 11 580 C1	8/18/94	Germany				✓
		WO 00/24406	5/4/00	PCT			✓	
		WO 00/15254	3/23/00	PCT			✓	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Naik R.S. et al., "Glycosylphosphatidylinositol Anchors of <i>Plasmodium falciparum</i> : Molecular Characterization and Naturally Elicited Antibody Response that May Provide Immunity to Malaria Pathogenesis", <i>The Journal of Experimental Medicine</i> 192(11):1563-1575 (2000)
	Vafai A., "Boosting Immune Response with a Candidate Varicella-Zoster Virus Glycoprotein Subunit Vaccine", <i>Vaccine</i> 13(14):1336-1338 (1995)
	Romero G. et al., "Anti-Inositolglycan Antibodies Selectively Block Some of the Actions of Insulin in Intact BC ₃ H1 Cells", <i>Proc. Natl. Acad. Sci. USA</i> 87:1476-1480 (1990)
	Schofield L. et al., "Synthetic GPI as a Candidate Anti-toxic Vaccine in a Model of Malaria", <i>Nature</i> 418:785-789 (2002)

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.